Epidemiology, Natural History, and Prevention

  • Sten H. Vermund
  • D. Peter Drotman


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Simian Immunodeficiency Virus Pneumocystis Carinii Pneumonia Perinatal Transmission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organization: Report on the global HIV/AIDS epidemic. Geneva: Who, 2000 Google Scholar
  2. 2.
    Quinn TC: Global burden of the HIV pandemic. Lancet 1996, 348:99–106PubMedCrossRefGoogle Scholar
  3. 3.
    Wawer MJ, Sewankambo NK, Berkley S, et al: HIV incidence in rural Rakai District Uganda. BMJ 1994, 308:171–173.PubMedCrossRefGoogle Scholar
  4. 4.
    Wawer MJ, Serwadda D, Musgrove SD, et al: Dynamics of spread of HIV-1 infection in a rural district of Uganda. BMJ 1991, 303:1303–1306PubMedCrossRefGoogle Scholar
  5. 5.
    Mann J, Tarantola DJM, Netter TW (eds.): AIDS in the World. Cambridge: Harvard University Press; 1992.Google Scholar
  6. 6.
    Nelson KE, Celentano DD, Suprasert S, et al: Risk factors for HIV infectioi among young adult men in northern Thailand. JAMA 1993, 270:955–96CPubMedCrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention: US HIV and AIDS cases reported through December 1995. In HIV/AIDS Surveillance Report. 1995, 7(2): 1–36.Google Scholar
  8. 8.
    Rosenberg PS, Biggar RJ:Trends in HIV incidence among young adults in the United States. JAMA 1998, 279:1894–1899.PubMedCrossRefGoogle Scholar
  9. 9.
    National Survey of Adolescent Men, 15–19 Year Olds, 1988, and the National Survey of Family Growth, 15–19 Year Olds, 1988. Washington, DC: National Center for Health Statistics, Centers for Disease Control and Prevention; 1989.Google Scholar
  10. 10.
    Centers for Disease Control and Prevention: National HIV Serosurveillance Summary: Results through 1992. 1992, 34:1–38.Google Scholar
  11. 11.
    Karon JM, et al.: Prevalence of HIV infection in the United States, 1984–1992. JAMA 1996, 276:126–131.PubMedCrossRefGoogle Scholar
  12. 12.
    Vermund SH: Changing estimates of HIV-1 seroprevalence in the United States. J NIH Res 1991, 3[Jul]:77–81.Google Scholar
  13. 13.
    Selik RM, Chu SY, Buehler JW: HIV infection as leading cause of death among young adults in US cities and states. JAMA 1993, 263:2991–2994.CrossRefGoogle Scholar
  14. 14.
    Vermund SH: Rising HIV-mortality in young Americans. JAMA 1993, 269:3034–3035.PubMedCrossRefGoogle Scholar
  15. 15.
    National Center for Health Statistics: Advance report of final monthly statistics, 1991. Mon Vital Stat Rep (Suppl) 1993, 42[2].Google Scholar
  16. 16.
    Osmond DH, Page K, Wiley J, et al.: Human immunodeficiency virus infection in homosexual and bisexual men 18 to 29 years of age: The San Francisco Young Men’s Health Study. Am J Public Health 1994, 84:1933–1937.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenberg PS, Levy ME, Brundage JF, et al.: Population-based monitoring of an urban HIV/AIDS epidemic: Magnitude and trends in the District of Columbia. JAMA 1992, 268:495–503.PubMedCrossRefGoogle Scholar
  18. 18.
    Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 [RR-17]: 1–19.Google Scholar
  19. 19.
    Bowler S, Sheon AR, D’Angelo U, Vermund SH: HIV and AIDS among adolescents in the United States: Increasing risk in the 1990s. J Adolesc 1992, 15:345–371.PubMedCrossRefGoogle Scholar
  20. 20.
    Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993, 262:1011–1018.PubMedCrossRefGoogle Scholar
  21. 21.
    Saag MS, Holodniy M, Kuritzkes DR, et al: HIV viral load markers in clinical practice. Nature Med 1996, 2:625–629.PubMedCrossRefGoogle Scholar
  22. 22.
    Pantaleo G, Graziosi C, Fanci AS: New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327–335.PubMedCrossRefGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention [PHS Task Force]: Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989, 38[S-5]:1–9.Google Scholar
  24. 24.
    Hirschel B, Lazzarin A, Chopard P, et al.: A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991, 324:1079–1083.PubMedCrossRefGoogle Scholar
  25. 25.
    Phair JP, Muhoz A, Detels R, et al.: The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990, 322:161–165.PubMedCrossRefGoogle Scholar
  26. 26.
    Muhoz A, Schrager LK, Bacellar H, et al: Trends and explanatory factors for the incidence of initial AIDS-defining outcomes in the Multicenter AIDS Cohort Study: 1984–1991. Am J Epidemiol 1993, 137:423–438.Google Scholar
  27. 27.
    Vermund SH, Kelley KF, Klein RS, et al.: High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 1991, 165:392–400.PubMedGoogle Scholar
  28. 28.
    Klein RD, Ho GY, Vermund SH, et al.: Squamous intraepithelial lesions and genital human papillomavirus infection in women with HIV infection. J Infect Dis 1994, 170(6): 1404–1409.PubMedCrossRefGoogle Scholar
  29. 29.
    Muhoz A, Kirby AJ, He YD, et al.: Long term survivors with HIV-1 infection: Incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:496–505.CrossRefGoogle Scholar
  30. 30.
    Elias CJ, Heise L: The Development of Microbicides: A New Method of HIV Prevention for Women. New York: The Population Council, 1993, Programs Division Working Paper no. 6.Google Scholar
  31. 31.
    Grosskurth H, Mosha F, Todd J, et al.: Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: Randomized controlled trial. Lancet 1995, 346:530–536.PubMedCrossRefGoogle Scholar
  32. 32.
    Minkoff H, Burns DN, Landesman S, et al: The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995, 173:585–589.PubMedCrossRefGoogle Scholar
  33. 33.
    Biggar RJ, Miotti PG, Taha TE, et al.: Perinatal intervention trial in Africa: Effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647–1650.PubMedCrossRefGoogle Scholar
  34. 34.
    Connor EM, Spering RS, Gilber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173–1180.PubMedCrossRefGoogle Scholar
  35. 35.
    Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795–802.PubMedGoogle Scholar
  36. 36.
    Kaplan EH: Needle exchange or needless exchange? Infect Agents Dis 1992, 1:92–98.PubMedGoogle Scholar
  37. 37.
    Hoth DF, Bolognesi DP, Corey L, Vermund SH: HIV vaccine development: A progress report. Ann Intern Med 1994, 121:603–611.PubMedCrossRefGoogle Scholar
  38. 38.
    Myers G, Korber B: The future of HIV. In Morse SS (ed.): Evolutionary Biology of Viruses. New York: Raven Press, 1994.Google Scholar
  39. 39.
    Vermund SH, Schultz AM, Hoff R: Prevention of HIV/AIDS with vaccines. Curr Opin Infect Dis 1994, 7:82–94.CrossRefGoogle Scholar
  40. 40.
    Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in health care workers after percutaneous expsoure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1542–1543.CrossRefGoogle Scholar
  41. 41.
    Tokars Jl, Bell DM, Culver DH, et al.: Percutaneous injuries during surgical procedures. JAMA 1992, 267:2899–2904.PubMedCrossRefGoogle Scholar
  42. 42.
    Panlilio AL, Welch BA, Bell DM, et al.: Blood and amniotic fluid contact sustained by obstetric personnel during deliveries. Am J Obstet Gynecol 1992, 167:703–708.PubMedGoogle Scholar
  43. 43.
    Cleveland JL, Lockwood SA, Gooch BF, et al.: Percutaneous injuries in dentistry: an observational study. J Am Dent Assoc 1995, 126:745–751.PubMedGoogle Scholar
  44. 44.
    Wong ES, Stotka JL, Chinchilli VM, et al.: Are universal precautions effective in reducing the number of occupational exposures among health care workers? a prospective study of physicians on a medical servicer. JAMA 1991,265:1123–1128.PubMedCrossRefGoogle Scholar
  45. 45.
    Marcus R, Culver DH, Bell DM, et al.: Risk of human immunodeficiency virus infection among emergecny department workers. Am J Med 1993, 94:363–370.PubMedCrossRefGoogle Scholar
  46. 46.
    Marcus R, Srivastava PU, Bell DM, et al.: Occupational blood contact among prehospital providers. Ann Emerg Med 1995, 25:776–779.PubMedCrossRefGoogle Scholar
  47. 47.
    Centers for Disease Control and Prevention: Public health service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 1998, 47[RR-07]: 1–39.Google Scholar

Selected Bibliography

  1. It is common for lecturers to want to report current statistics for the HIV/AIDS epidemic. Fortunately, there are three especially useful sources that anyone with access to the internet can check on the worldwide web.Google Scholar
  2. For HIV/AIDS statistics in the United States, the Centers for Disease Control and Prevention (CDC) is found at, then selecting the topic More Publications, Products, and Subscription Services. Also the CDC National AIDS Hotline can be reached by telephone at 1–800–342–2437 (1–800–344–7432 in Spanish and 1–800–243–7889 for TTY deaf access). Single copies of CDC publications, such as the annual HIV/AIDS Surveillance Report, are available free of charge from the CDC National AIDS Clearinghouse, PO Box 6003,Google Scholar
  3. Rockville, MD 20849–6003, or by telephone at 1–800–458–5231Google Scholar
  4. For recent research findings summarized in press releases and other documents, one can access the web site within the gopher URL of the National Institute of Allergy and Infectious Diseases at, which is updated regularly.
  5. The World Health Organization (WHO) web site is at and the UNAIDS web site at provides and the most recent worldwide HIV/AIDS surveillance statistics.

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Sten H. Vermund
  • D. Peter Drotman

There are no affiliations available

Personalised recommendations